Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8523 |
High Similarity |
NPD9605 |
Phase 3 |
0.8105 |
Intermediate Similarity |
NPD338 |
Approved |
0.8092 |
Intermediate Similarity |
NPD283 |
Approved |
0.8052 |
Intermediate Similarity |
NPD339 |
Approved |
0.8028 |
Intermediate Similarity |
NPD9632 |
Phase 3 |
0.7987 |
Intermediate Similarity |
NPD242 |
Approved |
0.7885 |
Intermediate Similarity |
NPD169 |
Phase 2 |
0.7792 |
Intermediate Similarity |
NPD3085 |
Phase 1 |
0.7755 |
Intermediate Similarity |
NPD252 |
Clinical (unspecified phase) |
0.7742 |
Intermediate Similarity |
NPD3086 |
Phase 3 |
0.7697 |
Intermediate Similarity |
NPD250 |
Approved |
0.7697 |
Intermediate Similarity |
NPD249 |
Approved |
0.7603 |
Intermediate Similarity |
NPD282 |
Approved |
0.7597 |
Intermediate Similarity |
NPD195 |
Approved |
0.7597 |
Intermediate Similarity |
NPD186 |
Discovery |
0.7568 |
Intermediate Similarity |
NPD1119 |
Phase 2 |
0.7562 |
Intermediate Similarity |
NPD4074 |
Clinical (unspecified phase) |
0.755 |
Intermediate Similarity |
NPD549 |
Approved |
0.7451 |
Intermediate Similarity |
NPD582 |
Approved |
0.745 |
Intermediate Similarity |
NPD194 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD3083 |
Approved |
0.7394 |
Intermediate Similarity |
NPD247 |
Clinical (unspecified phase) |
0.7386 |
Intermediate Similarity |
NPD2253 |
Discontinued |
0.7338 |
Intermediate Similarity |
NPD185 |
Approved |
0.7312 |
Intermediate Similarity |
NPD1369 |
Phase 2 |
0.7312 |
Intermediate Similarity |
NPD3107 |
Discontinued |
0.7312 |
Intermediate Similarity |
NPD1750 |
Clinical (unspecified phase) |
0.7294 |
Intermediate Similarity |
NPD4171 |
Clinical (unspecified phase) |
0.7289 |
Intermediate Similarity |
NPD7988 |
Suspended |
0.7279 |
Intermediate Similarity |
NPD1127 |
Approved |
0.7279 |
Intermediate Similarity |
NPD1128 |
Approved |
0.7261 |
Intermediate Similarity |
NPD7531 |
Clinical (unspecified phase) |
0.726 |
Intermediate Similarity |
NPD281 |
Approved |
0.7251 |
Intermediate Similarity |
NPD1412 |
Clinical (unspecified phase) |
0.725 |
Intermediate Similarity |
NPD536 |
Clinical (unspecified phase) |
0.7244 |
Intermediate Similarity |
NPD166 |
Approved |
0.7208 |
Intermediate Similarity |
NPD193 |
Suspended |
0.7188 |
Intermediate Similarity |
NPD353 |
Discontinued |
0.7178 |
Intermediate Similarity |
NPD2646 |
Discontinued |
0.7178 |
Intermediate Similarity |
NPD1732 |
Phase 3 |
0.7178 |
Intermediate Similarity |
NPD2624 |
Phase 2 |
0.7168 |
Intermediate Similarity |
NPD4716 |
Approved |
0.7159 |
Intermediate Similarity |
NPD6417 |
Clinical (unspecified phase) |
0.7126 |
Intermediate Similarity |
NPD4744 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD535 |
Approved |
0.6987 |
Remote Similarity |
NPD1118 |
Discontinued |
0.697 |
Remote Similarity |
NPD219 |
Phase 3 |
0.697 |
Remote Similarity |
NPD217 |
Approved |
0.697 |
Remote Similarity |
NPD218 |
Approved |
0.697 |
Remote Similarity |
NPD216 |
Approved |
0.697 |
Remote Similarity |
NPD220 |
Clinical (unspecified phase) |
0.6957 |
Remote Similarity |
NPD548 |
Clinical (unspecified phase) |
0.6899 |
Remote Similarity |
NPD1117 |
Clinical (unspecified phase) |
0.6889 |
Remote Similarity |
NPD2632 |
Approved |
0.6889 |
Remote Similarity |
NPD2631 |
Clinical (unspecified phase) |
0.6889 |
Remote Similarity |
NPD2630 |
Approved |
0.6882 |
Remote Similarity |
NPD1777 |
Approved |
0.6882 |
Remote Similarity |
NPD1776 |
Approved |
0.6846 |
Remote Similarity |
NPD78 |
Approved |
0.6846 |
Remote Similarity |
NPD9544 |
Approved |
0.6842 |
Remote Similarity |
NPD2647 |
Phase 3 |
0.6839 |
Remote Similarity |
NPD5666 |
Phase 2 |
0.6788 |
Remote Similarity |
NPD214 |
Approved |
0.6788 |
Remote Similarity |
NPD213 |
Clinical (unspecified phase) |
0.6781 |
Remote Similarity |
NPD9606 |
Approved |
0.6781 |
Remote Similarity |
NPD578 |
Discontinued |
0.6735 |
Remote Similarity |
NPD9607 |
Approved |
0.6645 |
Remote Similarity |
NPD1085 |
Approved |
0.6645 |
Remote Similarity |
NPD1775 |
Approved |
0.6644 |
Remote Similarity |
NPD2221 |
Clinical (unspecified phase) |
0.6625 |
Remote Similarity |
NPD1430 |
Approved |
0.6625 |
Remote Similarity |
NPD1431 |
Approved |
0.6603 |
Remote Similarity |
NPD209 |
Clinical (unspecified phase) |
0.6593 |
Remote Similarity |
NPD5684 |
Clinical (unspecified phase) |
0.6593 |
Remote Similarity |
NPD5682 |
Phase 3 |
0.6593 |
Remote Similarity |
NPD5683 |
Clinical (unspecified phase) |
0.6577 |
Remote Similarity |
NPD9290 |
Approved |
0.6577 |
Remote Similarity |
NPD9409 |
Discontinued |
0.6575 |
Remote Similarity |
NPD9406 |
Approved |
0.6568 |
Remote Similarity |
NPD546 |
Clinical (unspecified phase) |
0.6538 |
Remote Similarity |
NPD545 |
Clinical (unspecified phase) |
0.6516 |
Remote Similarity |
NPD248 |
Discontinued |
0.651 |
Remote Similarity |
NPD580 |
Discontinued |
0.6503 |
Remote Similarity |
NPD7158 |
Phase 1 |
0.6486 |
Remote Similarity |
NPD4054 |
Clinical (unspecified phase) |
0.6463 |
Remote Similarity |
NPD9374 |
Approved |
0.6452 |
Remote Similarity |
NPD9633 |
Phase 3 |
0.6438 |
Remote Similarity |
NPD9373 |
Approved |
0.6438 |
Remote Similarity |
NPD9359 |
Approved |
0.6438 |
Remote Similarity |
NPD9358 |
Approved |
0.6438 |
Remote Similarity |
NPD1808 |
Phase 1 |
0.6433 |
Remote Similarity |
NPD547 |
Clinical (unspecified phase) |
0.6405 |
Remote Similarity |
NPD579 |
Clinical (unspecified phase) |
0.64 |
Remote Similarity |
NPD307 |
Approved |
0.6393 |
Remote Similarity |
NPD1692 |
Approved |
0.6364 |
Remote Similarity |
NPD9408 |
Phase 3 |
0.6351 |
Remote Similarity |
NPD9086 |
Approved |
0.6312 |
Remote Similarity |
NPD1121 |
Approved |
0.6312 |
Remote Similarity |
NPD1120 |
Approved |
0.6301 |
Remote Similarity |
NPD8955 |
Approved |
0.6301 |
Remote Similarity |
NPD8954 |
Approved |
0.6287 |
Remote Similarity |
NPD775 |
Approved |
0.6282 |
Remote Similarity |
NPD870 |
Clinical (unspecified phase) |
0.6264 |
Remote Similarity |
NPD516 |
Clinical (unspecified phase) |
0.6258 |
Remote Similarity |
NPD3695 |
Approved |
0.6258 |
Remote Similarity |
NPD3696 |
Approved |
0.6213 |
Remote Similarity |
NPD3708 |
Phase 2 |
0.6184 |
Remote Similarity |
NPD9288 |
Approved |
0.6184 |
Remote Similarity |
NPD9292 |
Approved |
0.6184 |
Remote Similarity |
NPD9289 |
Approved |
0.6184 |
Remote Similarity |
NPD76 |
Approved |
0.6169 |
Remote Similarity |
NPD4262 |
Discontinued |
0.6145 |
Remote Similarity |
NPD4240 |
Approved |
0.6136 |
Remote Similarity |
NPD5768 |
Phase 2 |
0.6133 |
Remote Similarity |
NPD9584 |
Phase 2 |
0.6092 |
Remote Similarity |
NPD3697 |
Discontinued |
0.6087 |
Remote Similarity |
NPD6381 |
Phase 2 |
0.6082 |
Remote Similarity |
NPD7842 |
Phase 2 |
0.6064 |
Remote Similarity |
NPD1063 |
Phase 2 |
0.6054 |
Remote Similarity |
NPD9417 |
Phase 3 |
0.6054 |
Remote Similarity |
NPD9416 |
Phase 3 |
0.6012 |
Remote Similarity |
NPD1731 |
Clinical (unspecified phase) |
0.6 |
Remote Similarity |
NPD2152 |
Clinical (unspecified phase) |
0.5977 |
Remote Similarity |
NPD2180 |
Approved |
0.5959 |
Remote Similarity |
NPD9626 |
Clinical (unspecified phase) |
0.5956 |
Remote Similarity |
NPD3081 |
Clinical (unspecified phase) |
0.5947 |
Remote Similarity |
NPD7138 |
Phase 2 |
0.5933 |
Remote Similarity |
NPD9375 |
Discontinued |
0.5924 |
Remote Similarity |
NPD798 |
Discontinued |
0.5909 |
Remote Similarity |
NPD2604 |
Approved |
0.5905 |
Remote Similarity |
NPD6036 |
Suspended |
0.5893 |
Remote Similarity |
NPD2179 |
Discontinued |
0.5862 |
Remote Similarity |
NPD231 |
Clinical (unspecified phase) |
0.5824 |
Remote Similarity |
NPD171 |
Discontinued |
0.5821 |
Remote Similarity |
NPD2965 |
Clinical (unspecified phase) |
0.5817 |
Remote Similarity |
NPD5080 |
Phase 2 |
0.5813 |
Remote Similarity |
NPD515 |
Phase 1 |
0.5806 |
Remote Similarity |
NPD9360 |
Approved |
0.5793 |
Remote Similarity |
NPD5340 |
Clinical (unspecified phase) |
0.5792 |
Remote Similarity |
NPD2877 |
Clinical (unspecified phase) |
0.5792 |
Remote Similarity |
NPD2876 |
Phase 3 |
0.578 |
Remote Similarity |
NPD6840 |
Approved |
0.5778 |
Remote Similarity |
NPD3130 |
Discontinued |
0.5772 |
Remote Similarity |
NPD1816 |
Clinical (unspecified phase) |
0.5769 |
Remote Similarity |
NPD5079 |
Phase 2 |
0.5754 |
Remote Similarity |
NPD5321 |
Phase 3 |
0.575 |
Remote Similarity |
NPD4812 |
Phase 1 |
0.5745 |
Remote Similarity |
NPD1046 |
Clinical (unspecified phase) |
0.5742 |
Remote Similarity |
NPD1368 |
Approved |
0.5735 |
Remote Similarity |
NPD2824 |
Phase 2 |
0.5731 |
Remote Similarity |
NPD9627 |
Approved |
0.5705 |
Remote Similarity |
NPD237 |
Clinical (unspecified phase) |
0.5705 |
Remote Similarity |
NPD9291 |
Approved |
0.5698 |
Remote Similarity |
NPD1730 |
Discontinued |
0.565 |
Remote Similarity |
NPD5665 |
Clinical (unspecified phase) |
0.5632 |
Remote Similarity |
NPD4183 |
Phase 3 |
0.5632 |
Remote Similarity |
NPD4182 |
Phase 3 |
0.5625 |
Remote Similarity |
NPD2903 |
Clinical (unspecified phase) |
0.5625 |
Remote Similarity |
NPD2902 |
Phase 2 |
0.5614
|
Remote Similarity |
NPD1451 |
Approved |